Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)

被引：12
|
作者：
Altorki, N. [1 ]
Borczuk, A. [1 ]
Saxena, A. [1 ]
Port, J. [1 ]
Stiles, B. [1 ]
Lee, B. [1 ]
Sanfilippo, N. [1 ]
Ko, E. [1 ]
Scheff, R. [1 ]
Pua, B. [1 ]
Gruden, J. [1 ]
Christos, P. [1 ]
Spinelli, C. [1 ]
Gakuria, J. [1 ]
Mittal, V. [1 ]
Mcgraw, T. [1 ]
Formenti, S. [1 ]
机构：
[1] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
D O I：
10.1016/j.jtho.2019.08.1597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-92
引用
收藏
页码：S746 / S746
页数：1
相关论文
共 15 条
  • [1] Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574)
    Tsakiridis, T.
    Isfahanian, N.
    Nguyen, N.
    Wright, J.
    Hanna, W.
    Swaminath, A.
    Shargal, Y.
    Agzaraian, J.
    Wierzbicki, M.
    Chow, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S70 - S71
  • [2] Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708)
    Zwart, K.
    Braat, M. N. G. J. A.
    van der Baan, F. H.
    May, A. M.
    Roodhart, J. M. L.
    Al-Toma, D.
    Otten, J. M. M. B.
    Los, M.
    Oostergo, T.
    Fijneman, R. J. A.
    van Dodewaard-de Jong, J. M.
    Punt, C. J. A.
    Meijer, G.
    Lagendijk, J. J. W.
    Koopman, M.
    Intven, M.
    Bol, G. M.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 49
  • [3] A PHASE 2 STUDY OF DURVALUMAB COMBINED WITH CHEMOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN PATIENTS WITH OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) (SABRCURE TRIAL)
    Chen, Ming
    Ma, Honglian
    Du, Xianghui
    Xu, Yujin
    Ji, Yongling
    Song, Zhengbo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A729 - A729
  • [4] PHASE I STUDY OF NEO-ADJUVANT STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OPERABLE PATIENTS WITH BORDERLINE RESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA- NSCLC) (LINNEARRE I STUDY: NCT02433574)
    Isfahanian, Naghmeh
    Nguyen, Nhu-Tram
    Vansantvoort, Jasmin
    Wright, James
    Hanna, Wael
    Swaminath, Anand
    Shargall, Yaron
    Schieman, Colin
    Finley, Chritian
    Wierzbicki, Marcin
    Chow, Tom
    Okawara, Gordon
    Quan, Kimmen
    Tsakiridis, Theos
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S58 - S59
  • [5] Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID)
    Hallqvist, A.
    Koyi, H.
    de Petris, L.
    Lindberg, K.
    Farooqi, S.
    Helland, A.
    Wikstrom, A.
    Johansson, M.
    Planck, M.
    Lindberg, L.
    Yksnoy, O.
    Gronberg, B. H.
    Helbekkmo, N.
    Nyman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S729 - S730
  • [6] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
    Altorki, Nasser K.
    McGraw, Timothy E.
    Borczuk, Alain C.
    Saxena, Ashish
    Port, Jeffrey L.
    Stiles, Brendon M.
    Lee, Benjamin E.
    Sanfilippo, Nicholas J.
    Scheff, Ronald J.
    Pua, Bradley B.
    Gruden, James F.
    Christos, Paul J.
    Spinelli, Cathy
    Gakuria, Joyce
    Uppal, Manik
    Binder, Bhavneet
    Elemento, Olivier
    Ballman, Karla, V
    Formenti, Silvia C.
    LANCET ONCOLOGY, 2021, 22 (06): : 824 - 835
  • [7] Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
    Hill, Colin S.
    Rosati, Lauren M.
    Hu, Chen
    Fu, Wei
    Sehgal, Shuchi
    Hacker-Prietz, Amy
    Wolfgang, Christopher L.
    Weiss, Matthew J.
    Burkhart, Richard A.
    Hruban, Ralph H.
    De Jesus-Acosta, Ana
    Le, Dung T.
    Zheng, Lei
    Laheru, Daniel A.
    He, Jin
    Narang, Amol K.
    Herman, Joseph M.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (04) : 2456 - 2468
  • [8] Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
    Colin S. Hill
    Lauren M. Rosati
    Chen Hu
    Wei Fu
    Shuchi Sehgal
    Amy Hacker-Prietz
    Christopher L. Wolfgang
    Matthew J. Weiss
    Richard A. Burkhart
    Ralph H. Hruban
    Ana De Jesus-Acosta
    Dung T. Le
    Lei Zheng
    Daniel A. Laheru
    Jin He
    Amol K. Narang
    Joseph M. Herman
    Annals of Surgical Oncology, 2022, 29 : 2456 - 2468
  • [9] Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA NoneSmall-Cell Lung Cancer (NSCLC): KEYNOTE-867
    Jabbour, S. K.
    Houghton, B.
    Robinson, A. G.
    Quantin, X.
    Wehler, T.
    Kowalski, D.
    Ahn, M. J.
    Erman, M.
    Giaccone, G.
    Borghaei, H.
    McLean, J.
    Zhang, J.
    Souza, F.
    Decker, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E135 - E136
  • [10] NAUTIKA1: A Multicenter Phase II Study with a PD-L1+Cohort of Patients Receiving Atezolizumab (Atezo) with Low-Dose Stereotactic Body Radiation Therapy (SBRT) as Neoadjuvant Therapy for Resectable Stage IB-III NSCLC
    Tian, S.
    Kozono, D. E.
    Ohri, N.
    Jolly, S.
    Johnson, B. E.
    Chaft, J.
    Toloza, E. M.
    Ding, B.
    Ngiam, C.
    Schulz, K.
    Bara, I.
    Lee, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E392 - E393
12